Mounjaro vs Ozempic — which one in 2026?

Mounjaro or Ozempic? Both dominate every conversation about weight loss medication right now, and for good reason — both are effective in a way that older treatments simply weren't. But they are not the same drug, and in 2026 the evidence landscape has shifted enough that there are clear, data-backed ways to think through the choice.

The first thing worth understanding is that these are different drugs with different mechanisms. Tirzepatide (the active ingredient in both Mounjaro for diabetes and Zepbound for weight loss) is a dual agonist — it activates two receptors, GIP and GLP-1. Semaglutide (Ozempic for diabetes, Wegovy for weight loss) activates only the GLP-1 receptor. That extra receptor isn't a minor detail — researchers believe the dual mechanism is why tirzepatide consistently produces greater weight loss, and it may also explain why tirzepatide tends to have a somewhat friendlier GI side effect profile despite being the stronger drug.

For years, comparing these two drugs meant stacking data from separate trials run in different populations under different conditions. That always left an asterisk on any comparison. In 2025, that changed. SURMOUNT-5 was published — the first randomised head-to-head trial directly comparing tirzepatide and semaglutide injection in the same study. There is no longer any need to guess. The direct comparison confirmed what the indirect data suggested: tirzepatide produces greater weight loss.

The comparison below draws on SURMOUNT-1, SURMOUNT-5, STEP 1, the SELECT cardiovascular outcomes trial, and the newer oral formulation studies — covering weight loss, side effects, heart outcomes, cost, and how to choose.

The weight loss numbers

In the SURMOUNT-1 trial — 2,539 participants, 72 weeks, no diabetes — people taking tirzepatide at its highest dose lost an average of 20.9% of their body weight. To put that in concrete terms: for a 220 lb person, that's roughly 46 lbs — meaningfully larger than what any previous weight loss drug had achieved in clinical trials. The dual GIP+GLP-1 mechanism appears to produce stronger appetite suppression and a greater overall metabolic effect than GLP-1 alone.

In the STEP 1 trial — 1,961 participants, 68 weeks — participants taking semaglutide injection lost an average of 14.9%. For the same 220 lb person, that's around 33 lbs. That is still a clinically meaningful result, and represents a major advance over older treatments. But there is a real gap between 14.9% and 20.9% — about 6 to 7 percentage points — and it shows up consistently across every study that has examined both drugs.

SURMOUNT-5 settled the indirect comparison debate definitively. In that direct head-to-head trial, participants randomised to tirzepatide lost significantly more weight than those on semaglutide injection — roughly 47% more on a relative basis. This is not a marginal edge. It is a consistent, statistically significant difference. The trial only ran for 72 weeks and only measured weight outcomes, but on the primary question of which drug produces greater weight loss, the data is now clear.

Semaglutide now also comes in a daily pill form (oral Wegovy, 25mg, FDA-approved December 2025). In the OASIS 4 trial, participants taking oral semaglutide lost an average of 13.6% — slightly less than the injection, but still a substantial result for a pill taken once daily rather than a weekly injection. This changes the cost and convenience calculation significantly.

These figures are trial averages across large populations. Individual results vary considerably — some participants lose far more, others less, depending on starting weight, diet, activity level, and how well they tolerate full-dose escalation. The percentages give you the central tendency from well-run studies, not a prediction for any individual.

Side effects: what you're actually getting into

Both drugs work by activating GLP-1 receptors in the gut and brain, which means both share a similar side effect profile. Nausea, diarrhoea, vomiting, and constipation are the most commonly reported issues, and they are real — this is not a category where either drug gets a clean bill of tolerability. What matters more is the pattern: for most people, GI side effects are worst during the dose escalation period, typically the first 8 to 12 weeks, and they improve substantially once you reach and stabilise on your maintenance dose. The escalation schedules for both drugs are specifically designed to minimise this disruption by starting low and stepping up slowly over several months.

Looking at the trial data, semaglutide participants reported higher nausea rates (around 44% in STEP 1) compared to tirzepatide participants (around 31% in SURMOUNT-1). Similar patterns showed up across diarrhoea, vomiting, and constipation. That said, these numbers come from different trials with different populations — this is not a controlled head-to-head comparison of side effects, and SURMOUNT-5 didn't publish detailed side-effect breakdowns in the same way. The comparison below is indicative, not definitive.

The practical takeaway is that most people who stick with either drug find the side effects manageable, particularly after the initial adjustment period. A minority find them intolerable at higher doses and either stay at a lower maintenance dose or switch drugs. There is no reliable way to predict in advance which group you will fall into.

Figures from separate trials — SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide). These are not from a controlled head-to-head comparison and should be read as indicative.

The cardiovascular question — where semaglutide stands alone

This is the section that shifts the comparison significantly for a specific group of people. The SELECT trial enrolled 17,604 participants — all with overweight or obesity plus established cardiovascular disease (meaning a prior heart attack, stroke, or diagnosed heart condition) — and followed them for approximately 40 months. The result: participants taking semaglutide injection experienced a 20% reduction in major adverse cardiovascular events compared to placebo. That is a reduction in actual heart attacks and strokes, not just a metabolic surrogate.

No other weight loss drug has this level of cardiovascular outcome evidence. This is not a claim about weight loss or metabolic markers — it is a randomised controlled trial at scale showing that semaglutide reduces the rate at which people with existing heart disease have major cardiac events. The FDA approved semaglutide (as Wegovy) specifically for cardiovascular risk reduction on the basis of SELECT, making it the first weight loss drug to carry that indication.

Tirzepatide very likely has cardiovascular benefits too — the mechanism suggests it would, and early metabolic data is encouraging — but the large outcomes trial (SURPASS-CVOT) is still running as of mid-2026. For someone with existing heart disease who is deciding between these two drugs today, the SELECT data is a meaningful differentiator. The evidence exists for semaglutide. It does not yet exist for tirzepatide at the same scale.

Cost: the picture has changed

The cost comparison between these two drugs used to be fairly simple. Tirzepatide (Zepbound) came in slightly cheaper than semaglutide injection (Wegovy) on list price, and Lilly's direct-pay programme brought Zepbound down to around $650 per month without insurance. Wegovy's list price sat around $1,350 per month, making it the pricier option. Neither was affordable without either strong insurance coverage or access to savings programmes.

Oral Wegovy changed that. At approximately $149 per month self-pay, it is roughly 77% cheaper than Zepbound via LillyDirect and over 89% cheaper than Wegovy injection at list price. That is not a small difference — it's the difference between a drug being financially accessible or not for most people without insurance coverage. The trade-off is that in clinical trials, participants on oral semaglutide lost an average of 13.6% versus 20.9% for tirzepatide injection. Whether that trade-off makes sense depends entirely on your financial situation and how much the additional weight loss matters to you.

Foundayo (orforglipron), which received FDA approval in April 2026, is also available at around $349 per month — another oral GLP-1 option in a similar price bracket, though with somewhat lower trial weight loss figures of 7.9–9.4%. The oral market is expanding, and prices are likely to come down further as competition increases.

Insurance coverage varies enormously. Many plans still exclude weight loss medications entirely. Where coverage does exist, copays can bring costs down dramatically — oral Wegovy can reach as low as $25/month with insurance. If you have coverage, the cost comparison looks very different than it does at list price.

How to think about choosing between them

The right choice depends on individual medical history, risk factors, budget, and tolerance for injections. Here's how the data frames the decision.

If weight loss is the primary goal and injections are not a barrier, tirzepatide has the clearer edge. The SURMOUNT-5 head-to-head settled that argument. In clinical trials, participants on tirzepatide lost roughly 6 to 7 percentage points more than those on semaglutide injection, and the direct comparison confirmed that gap is real and statistically significant. For someone who wants to maximise the weight loss outcome from a once-weekly injection, the data points consistently in one direction.

If heart health is a significant concern — particularly if there is already a diagnosis of cardiovascular disease, a prior heart attack, or a prior stroke — the SELECT trial data changes the conversation. Semaglutide injection is the only weight loss drug that has demonstrated a reduction in actual cardiovascular events in a large outcomes trial. That is not a minor footnote; for someone in that situation, it is potentially the most important piece of data on this page. Tirzepatide may well show similar benefits when its own CV outcomes trial reports, but that data does not exist yet.

If cost is the dominant factor, the comparison shifts entirely. Oral Wegovy at $149 per month produced 13.6% weight loss — meaningfully less than tirzepatide injection, but still a substantial result and available without a weekly needle. For someone who cannot afford $650+ per month, the choice between oral semaglutide and no treatment is straightforward. For someone comparing $149 per month to $650 per month, the question becomes whether the additional 7 percentage points of weight loss is worth the cost difference to them personally.

If injections are a hard barrier — whether due to needle phobia, lifestyle, or practicality — then both oral Wegovy and Foundayo become serious options. Both are daily pills, both are in the $149–$349 range, and both represent a real advance in making GLP-1 therapy more accessible. The weight loss outcomes are lower than the injections, but for many people the practical sustainability of a daily pill outweighs a percentage-point difference in trial averages.